Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Mallinckrodt and Endo, drugmakers with a shared history of facing bankruptcy and U.S. opioid litigation, have agreed to merge ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...

Both drugmakers have emerged from bankruptcies in recent years and dealt with litigation related to their production of opioids. Dublin-headquartered Mallinckrodt is taking over smaller rival Endo ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

(Reuters) -Mallinckrodt and Endo, drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced plans Thursday to join forces in a deal valued at $6.7 billion.

While Mallinckrodt emerged from its second bankruptcy in November 2023, Endo returned last year. The drugmakers are discussing the terms of a transaction that would give each of them roughly 50% ...

Bengaluru: Mallinckrodt and Endo , drugmakers with a shared history of bankruptcy and U.S. opioid litigation, will merge in a deal valued at nearly $7 billion to boost scale for selling their ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders ...